Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Feb 25

PMID 35209007

Authors

Chen Ma

Fenfang Hong

Shulong Yang

Affiliations

Soon will be listed here.

Abstract

The amyloid hypothesis of Alzheimer's disease has long been the predominant theory, suggesting that Alzheimer's disease is caused by the accumulation of amyloid beta protein (Aβ) in the brain, leading to neuronal toxicity in the central nervous system (CNS). Because of breakthroughs in molecular medicine, the amyloid pathway is thought to be central to the pathophysiology of Alzheimer's disease (AD). Currently, it is believed that altered biochemistry of the Aβ cycle remains a central biological feature of AD and is a promising target for treatment. This review provides an overview of the process of amyloid formation, explaining the transition from amyloid precursor protein to amyloid beta protein. Moreover, we also reveal the relationship between autophagy, cerebral blood flow, ACHE, expression of LRP1, and amyloidosis. In addition, we discuss the detailed pathogenesis of amyloidosis, including oxidative damage, tau protein, NFTs, and neuronal damage. Finally, we list some ways to treat AD in terms of decreasing the accumulation of Aβ in the brain.

Citing Articles

Could Blood Transfusion Increase the Risk of Alzheimer's Disease? A Narrative Review.

Li X, Pei R, Fei Z, Chen Z, Lin F, Sun P Healthcare (Basel). 2025; 13(5).

PMID: 40077014 PMC: 11898722. DOI: 10.3390/healthcare13050452.

Behavioral and pathological characteristics of 5xFAD female mice in the early stage.

Zhu C, Liu X Sci Rep. 2025; 15(1):6924.

PMID: 40011556 PMC: 11865263. DOI: 10.1038/s41598-025-90335-2.

Advancing Alzheimer's Therapy: Computational strategies and treatment innovations.

Paul J, Malik A, Azmal M, Gulzar T, Afghan M, Talukder O IBRO Neurosci Rep. 2025; 18:270-282.

PMID: 39995567 PMC: 11849200. DOI: 10.1016/j.ibneur.2025.02.002.

Hippocampal vascularization pattern and cerebral blood flow cooperatively modulate hippocampal tolerable amount of Aβ deposition in the occurrence of MCI.

Xu Y, Wei H, Du R, Wang R, Zhu Y, Zhao T Fluids Barriers CNS. 2025; 22(1):22.

PMID: 39994752 PMC: 11854383. DOI: 10.1186/s12987-025-00635-y.

Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer's Disease.

Abdelhamid M, Counts S, Zhou C, Hida H, Kim J, Michikawa M Nutrients. 2025; 17(3).

PMID: 39940416 PMC: 11820889. DOI: 10.3390/nu17030558.

References

Minati L, Edginton T, Bruzzone M, Giaccone G . Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen. 2009; 24(2):95-121. PMC: 10846154. DOI: 10.1177/1533317508328602. View

Marco-Contelles J, Unzeta M, Bolea I, Esteban G, Ramsay R, Romero A . ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. Front Neurosci. 2016; 10:294. PMC: 4923252. DOI: 10.3389/fnins.2016.00294. View

Hohenfeld C, Kuhn H, Muller C, Nellessen N, Ketteler S, Heinecke A . Changes in brain activation related to visuo-spatial memory after real-time fMRI neurofeedback training in healthy elderly and Alzheimer's disease. Behav Brain Res. 2019; 381:112435. DOI: 10.1016/j.bbr.2019.112435. View

Zhou R, Chen L, Yang H, Li L, Liu J, Chen L . Effect of High Cholesterol Regulation of LRP1 and RAGE on Aβ Transport Across the Blood-Brain Barrier in Alzheimer's Disease. Curr Alzheimer Res. 2021; 18(5):428-442. DOI: 10.2174/1567205018666210906092940. View

Du Y, Qu J, Zhang W, Bai M, Zhou Q, Zhang Z . Morin reverses neuropathological and cognitive impairments in APPswe/PS1dE9 mice by targeting multiple pathogenic mechanisms. Neuropharmacology. 2016; 108:1-13. DOI: 10.1016/j.neuropharm.2016.04.008. View

Halliwell B . Oxidative stress and neurodegeneration: where are we now?. J Neurochem. 2006; 97(6):1634-58. DOI: 10.1111/j.1471-4159.2006.03907.x. View

Blennow K, de Leon M, Zetterberg H . Alzheimer's disease. Lancet. 2006; 368(9533):387-403. DOI: 10.1016/S0140-6736(06)69113-7. View

Liu Y, Wang Y, Zha D . Brain Functional and Structural Changes in Alzheimer's Disease With Sleep Disorders: A Systematic Review. Front Psychiatry. 2021; 12:772068. PMC: 8591034. DOI: 10.3389/fpsyt.2021.772068. View

Maltsev A, Santockyte R, Bystryak S, Galzitskaya O . Activation of neuronal defense mechanisms in response to pathogenic factors triggering induction of amyloidosis in Alzheimer's disease. J Alzheimers Dis. 2013; 40(1):19-32. DOI: 10.3233/JAD-131562. View

10.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

11.

Simoni E, Bartolini M, Abu I, Blockley A, Gotti C, Bottegoni G . Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation. Future Med Chem. 2017; 9(10):953-963. DOI: 10.4155/fmc-2017-0039. View

12.

. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016; 12(4):459-509. DOI: 10.1016/j.jalz.2016.03.001. View

13.

Xia Y, Prokop S, Giasson B . "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies. Mol Neurodegener. 2021; 16(1):37. PMC: 8180161. DOI: 10.1186/s13024-021-00460-5. View

14.

Esquerda-Canals G, Roda A, Marti-Clua J, Montoliu-Gaya L, Rivera-Hernandez G, Villegas S . Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-β Burden. J Alzheimers Dis. 2019; 70(4):1069-1091. DOI: 10.3233/JAD-190484. View

15.

Glenner G, Wong C . Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochem Biophys Res Commun. 2012; 425(3):534-9. DOI: 10.1016/j.bbrc.2012.08.020. View

16.

Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V . Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease. J Magn Reson Imaging. 2019; 51(2):505-513. DOI: 10.1002/jmri.26810. View

17.

Arvanitakis Z, Shah R, Bennett D . Diagnosis and Management of Dementia: Review. JAMA. 2019; 322(16):1589-1599. PMC: 7462122. DOI: 10.1001/jama.2019.4782. View

18.

Forloni G, Artuso V, La Vitola P, Balducci C . Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. Mov Disord. 2016; 31(6):771-81. DOI: 10.1002/mds.26624. View

19.

Dougherty J, Wu J, Nichols R . Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci. 2003; 23(17):6740-7. PMC: 6740736. View

20.

Sadleir K, Kandalepas P, Buggia-Prevot V, Nicholson D, Thinakaran G, Vassar R . Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease. Acta Neuropathol. 2016; 132(2):235-256. PMC: 4947125. DOI: 10.1007/s00401-016-1558-9. View